Background: Sepsis, a leading cause of death in critically ill patients, is the result of complex interactions between the infecting microorganisms and the host responses that influence clinical outcomes. Optimal management requires early goal-oriented therapies and may benefit from individualized circulating biomarkers for early risk stratification. We evaluated the prognostic value of presepsin (sCD14-ST), a novel marker of bacterial infection. Methods: This is a nested case-control study of the multicenter, randomized ALBIOS trial that enrolled patients with severe sepsis or septic shock in 100 ICUs in Italy. We selected 50 survivors and 50 nonsurvivors at the time of ICU discharge (21±18 days) matched for age, sex, center and time of enrolment after the presence of inclusion criteria. EDTA-plasma samples were collected at days 1, 2 and 7 after enrolment to assay presepsin (immune-chemiluminescence assay PATHFAST Presepsin, URL 320 pg/mL, CV 5%, Mitsubishi Chemicals) and procalcitonin (PCT, Elecsys BRAHMS Cobas® PCT, URL 0.046 ng/mL, CV 8.8%, Roche Diagnostics) in a central laboratory. Results: Clinical characteristics were similar in the 2 groups, but non-survivors had a worse SOFA score at day 1. Patients with higher baseline presepsin had worse SOFA score, lower mean arterial pressure and diuresis. Early presepsin (d1) was higher in decedents (2268[1145-4305] pg/mL, median[Q1-Q3]) than in survivors (1184[855-2158] pg/mL, p=0.001) while PCT was not different (18.5[3.3-45.7] vs. 10.8[2.6-46.4] ng/mL, p=0.31). Presepsin decreased over time in survivors but remained elevated in non-survivors (974[674-1927] vs. 2551[1438-5624] pg/mL at d7, p=0.02 for time-survival interaction); PCT decreased similarly in the 2 groups (p=0.19). Differences in presepsin vs. outcome were more marked in patients enrolled 6-24 h after ICU admission, and in those with septic shock. Early presepsin had better prognostic accuracy than PCT (AUROC at d1, 0.69 vs. 0.56, p=0.07) and improved discrimination over clinical SOFA score. Conclusions: We provide first evidence in a multicenter clinical trial that early presepsin measurement provides relevant prognostic information in patients with severe sepsis or septic shock and may be of clinical importance for early risk stratification.

Presepsin (sCD14-ST) is an early predictor of outcome in patients with severe sepsis or septic shock : preliminary data from the Albumin Italian Outcome Sepsis (ALBIOS) study / M. Masson, P. Caironi, E. Spanuth, R. Thomae, R. Fumagalli, A. Pesenti, M. Romero, G. Tognoni, R. Latini, L. Gattinoni. ((Intervento presentato al convegno EuroMedLab tenutosi a Milano nel 2013.

Presepsin (sCD14-ST) is an early predictor of outcome in patients with severe sepsis or septic shock : preliminary data from the Albumin Italian Outcome Sepsis (ALBIOS) study

P. Caironi;A. Pesenti;L. Gattinoni
2013

Abstract

Background: Sepsis, a leading cause of death in critically ill patients, is the result of complex interactions between the infecting microorganisms and the host responses that influence clinical outcomes. Optimal management requires early goal-oriented therapies and may benefit from individualized circulating biomarkers for early risk stratification. We evaluated the prognostic value of presepsin (sCD14-ST), a novel marker of bacterial infection. Methods: This is a nested case-control study of the multicenter, randomized ALBIOS trial that enrolled patients with severe sepsis or septic shock in 100 ICUs in Italy. We selected 50 survivors and 50 nonsurvivors at the time of ICU discharge (21±18 days) matched for age, sex, center and time of enrolment after the presence of inclusion criteria. EDTA-plasma samples were collected at days 1, 2 and 7 after enrolment to assay presepsin (immune-chemiluminescence assay PATHFAST Presepsin, URL 320 pg/mL, CV 5%, Mitsubishi Chemicals) and procalcitonin (PCT, Elecsys BRAHMS Cobas® PCT, URL 0.046 ng/mL, CV 8.8%, Roche Diagnostics) in a central laboratory. Results: Clinical characteristics were similar in the 2 groups, but non-survivors had a worse SOFA score at day 1. Patients with higher baseline presepsin had worse SOFA score, lower mean arterial pressure and diuresis. Early presepsin (d1) was higher in decedents (2268[1145-4305] pg/mL, median[Q1-Q3]) than in survivors (1184[855-2158] pg/mL, p=0.001) while PCT was not different (18.5[3.3-45.7] vs. 10.8[2.6-46.4] ng/mL, p=0.31). Presepsin decreased over time in survivors but remained elevated in non-survivors (974[674-1927] vs. 2551[1438-5624] pg/mL at d7, p=0.02 for time-survival interaction); PCT decreased similarly in the 2 groups (p=0.19). Differences in presepsin vs. outcome were more marked in patients enrolled 6-24 h after ICU admission, and in those with septic shock. Early presepsin had better prognostic accuracy than PCT (AUROC at d1, 0.69 vs. 0.56, p=0.07) and improved discrimination over clinical SOFA score. Conclusions: We provide first evidence in a multicenter clinical trial that early presepsin measurement provides relevant prognostic information in patients with severe sepsis or septic shock and may be of clinical importance for early risk stratification.
Sepsis; Critical Care; Soluble CD14; Procalcitonin; Infection
Settore MED/41 - Anestesiologia
International Federation of Clinical Chemistry
European Federation of Laboratory Medicine
Presepsin (sCD14-ST) is an early predictor of outcome in patients with severe sepsis or septic shock : preliminary data from the Albumin Italian Outcome Sepsis (ALBIOS) study / M. Masson, P. Caironi, E. Spanuth, R. Thomae, R. Fumagalli, A. Pesenti, M. Romero, G. Tognoni, R. Latini, L. Gattinoni. ((Intervento presentato al convegno EuroMedLab tenutosi a Milano nel 2013.
Conference Object
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/254863
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact